These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 17618092

  • 1. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.
    Chawla G, Bansal AK.
    Eur J Pharm Sci; 2007 Sep; 32(1):45-57. PubMed ID: 17618092
    [Abstract] [Full Text] [Related]

  • 2. Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique.
    Boghra RJ, Kothawade PC, Belgamwar VS, Nerkar PP, Tekade AR, Surana SJ.
    Chem Pharm Bull (Tokyo); 2011 Sep; 59(4):438-41. PubMed ID: 21467670
    [Abstract] [Full Text] [Related]

  • 3. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 4. Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives.
    Chawla G, Bansal AK.
    Acta Pharm; 2008 Sep; 58(3):257-74. PubMed ID: 19103563
    [Abstract] [Full Text] [Related]

  • 5. Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate.
    Zhang ZL, Le Y, Wang JX, Chen JF.
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1357-64. PubMed ID: 21548718
    [Abstract] [Full Text] [Related]

  • 6. Investigation of the dissolution rate and oral bioavailability of atenolol-irbesartan co-amorphous systems.
    Song J, Bao R, Lin M, Li W, Zhao P, Liu X, Fu Q.
    Int J Pharm; 2024 Nov 15; 665():124704. PubMed ID: 39312985
    [Abstract] [Full Text] [Related]

  • 7. Molecular mobility study of amorphous and crystalline phases of a pharmaceutical product by thermally stimulated current spectrometry.
    Boutonnet-Fagegaltier N, Menegotto J, Lamure A, Duplaa H, Caron A, Lacabanne C, Bauer M.
    J Pharm Sci; 2002 Jun 15; 91(6):1548-60. PubMed ID: 12115853
    [Abstract] [Full Text] [Related]

  • 8. Effect of counterions on the properties of amorphous atorvastatin salts.
    Sonje VM, Kumar L, Puri V, Kohli G, Kaushal AM, Bansal AK.
    Eur J Pharm Sci; 2011 Nov 20; 44(4):462-70. PubMed ID: 21907794
    [Abstract] [Full Text] [Related]

  • 9. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T.
    Eur J Pharm Biopharm; 2013 Nov 20; 85(3 Pt B):873-81. PubMed ID: 23537574
    [Abstract] [Full Text] [Related]

  • 10. Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches.
    Pina MF, Pinto JF, Sousa JJ, Craig DQ, Zhao M.
    Int J Pharm; 2015 Mar 15; 481(1-2):114-24. PubMed ID: 25592956
    [Abstract] [Full Text] [Related]

  • 11. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ, Floyd PD, Dell'Orco PC.
    Int J Pharm; 2019 Jan 30; 555():100-108. PubMed ID: 30448307
    [Abstract] [Full Text] [Related]

  • 12. Phase behavior and oral bioavailability of amorphous Curcumin.
    Pawar YB, Shete G, Popat D, Bansal AK.
    Eur J Pharm Sci; 2012 Aug 30; 47(1):56-64. PubMed ID: 22609283
    [Abstract] [Full Text] [Related]

  • 13. Production of Irbesartan Nanocrystals by High Shear Homogenisation and Ultra-Probe Sonication for Improved Dissolution Rate.
    Sridhar K, Rahman H, Sosnik A, Mukherjee U, Natarajan T, Siram K, Krishnamoorthy B.
    Curr Drug Deliv; 2016 Aug 30; 13(5):688-97. PubMed ID: 26563944
    [Abstract] [Full Text] [Related]

  • 14. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P, Chawla G, Bansal AK.
    Mol Pharm; 2004 Aug 30; 1(6):406-13. PubMed ID: 16028352
    [Abstract] [Full Text] [Related]

  • 15. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB, Pikal MJ, Shanker RM, Bogner RH.
    Pharm Dev Technol; 2011 Jun 30; 16(3):187-200. PubMed ID: 20429826
    [Abstract] [Full Text] [Related]

  • 16. Effect of amorphization method on telmisartan solubility and the tableting process.
    Lepek P, Sawicki W, Wlodarski K, Wojnarowska Z, Paluch M, Guzik L.
    Eur J Pharm Biopharm; 2013 Jan 30; 83(1):114-21. PubMed ID: 23085331
    [Abstract] [Full Text] [Related]

  • 17. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
    Dengale SJ, Ranjan OP, Hussen SS, Krishna BS, Musmade PB, Gautham Shenoy G, Bhat K.
    Eur J Pharm Sci; 2014 Oct 01; 62():57-64. PubMed ID: 24878386
    [Abstract] [Full Text] [Related]

  • 18. Dissolution kinetics of glibenclamide glass.
    Salem MS, Najib NM, Hassan MA, Suleiman MS.
    Acta Pharm Hung; 1997 Jan 01; 67(1):13-7. PubMed ID: 9100388
    [Abstract] [Full Text] [Related]

  • 19. Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy.
    Cruz-Angeles J, Videa M, Martínez LM.
    AAPS PharmSciTech; 2019 Mar 18; 20(4):144. PubMed ID: 30887140
    [Abstract] [Full Text] [Related]

  • 20. Preparation and evaluation of metastable solid-state forms of lopinavir.
    Lemmer HJ, Liebenberg W.
    Pharmazie; 2013 May 18; 68(5):327-32. PubMed ID: 23802429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.